



## Altimune to Participate at Two Upcoming Investor Conferences

May 8, 2023

GAITHERSBURG, Md., May 08, 2023 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

- **JMP Securities Life Sciences Conference in New York, NY**

Tuesday, May 16, 2023

*Fireside chat at 9:00 am Eastern Time*

The session will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

- **Piper Sandler Spring Biopharma Symposium in Boston, MA**

Thursday, May 18, 2023

*One-on-one meetings only*

### About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit [www.altimmune.com](http://www.altimmune.com).

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

### Altimune Investor & Media Contact:

Richard Eisenstadt  
Chief Financial Officer  
Phone: 240-654-1450  
[reisenstadt@altimmune.com](mailto:reisenstadt@altimmune.com)



Source: Altimune, Inc